Bayer Animal Health Showcases Global Commitment to Transform Livestock Production at IPVS

Bayer's Practical Ingenuity Ensures Veterinarians and Producers are Equipped for Successful Swine Production in Highly Competitive Globalised Marketplace

VANCOUVER, July 22, 2010 - Bayer Animal Health today revealed their new commitment to the livestock
community at the 21st International Pig Veterinary Society (IPVS) Congress in
Vancouver, Canada.

"This year's congress highlights the complex and rapidly changing world
pig production operates in and the need for constant innovation from everyone
involved. At Bayer Animal Health, we recognise the significant challenges our
customers face in this dynamic environment. That is why we are making a
global commitment to ensuring our innovation, practical ingenuity and
scientific excellence are available to as many pig producers as possible,"
commented Jim Gerardot, Bayer's Global Marketing Head of Food Animal Products
and former livestock producer.

"With the objective of transforming livestock production sitting at the
heart of our business, we will be supporting the industry by providing full
access to Bayer's global knowledge and resources at a local level. We will be
providing the scientific information, educational opportunities, quality
products, services and innovative solutions needed to meet the challenges of
the changing environment, wherever they may be," added Jim Gerardot.

The need for continuing innovation and education was reinforced by Dr
Dermot Hayes of Iowa State University. "This year's meeting of international
experts shows us the latest developments in international trade, competition
for feed grain and the potential for major disruption as a result of disease
outbreaks. It is clear that the future of successful swine production will
depend on producers staying abreast of the latest developments in the field,
and rapidly adjusting their production techniques if they are to remain
competitive in this globalised marketplace."

Data presented at the IPVS 2010 meeting also confirmed that one of the
significant issues facing all swine producers remains coccidiosis. This
common disease is believed to be present in the majority of swine herds,
causes significant financial losses and remains a truly global issue.

In line with their commitment, and embracing the congress theme of
'Sharing Ideas - Advancing Pig Health', Bayer Animal Health also presented a
wide range of data at IPVS. A key paper was given by Dr Steven McOrist, whose
team studied the impact of treatment with Baycox 5% in an on-farm study of a
herd of more than 5,000 swine in a grower-finisher facility in Romania.
According to Dr McOrist, "Our study demonstrated the protective effects of
Baycox on gut health in treated pigs, with a significant drop in oocyst count
in piglets around weaning in the treated group (p < 0.01). There was also a
marked improvement in feed conversion in treated weaner-finisher pigs (2.41
vs. 2.63), with weight gains consistently and significantly better through to
day 150 and evidence of a protective effect against a late, moderate Lawsonia
exposure during the study."

Dr Bent Nielsen of Bayer Animal Health reinforced the importance of the
study stating, "Coccidiosis prevention is a critical piglet health practice.
This new information further demonstrates the added value that improving gut
health can have throughout the swine production system."

To view the full MMR release, including video interviews with leading
veterinary experts, please click here (bit.ly/IPVS2010)

About Bayer HealthCare

Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's
leading, innovative companies in the healthcare and medical products industry
and is based in Leverkusen, Germany. The company combines the global
activities of the Animal Health, Bayer Schering Pharma, Consumer Care and
Medical Care divisions. Bayer HealthCare's aim is to discover and manufacture
products that will improve human and animal health worldwide. Find more
information at www.bayerhealthcare.com.

With a turnover of EUR977 million (2009) Bayer HealthCare's Animal Health
Division is one of the world's leading manufacturers of veterinary drugs. The
division manufactures and markets more than 100 different veterinary drugs
and care products for livestock and companion animals.

Forward-Looking Statements

This news release contains forward-looking statements based on current
assumptions and forecasts made by Bayer Group management. Various known and
unknown risks, uncertainties and other factors could lead to material
differences between the actual future results, financial situation,
development or performance of the company and the estimates given here. These
factors include those discussed in our annual and interim reports to the
Frankfurt Stock Exchange and in our reports filed with the U.S. Securities
and Exchange Commission (including our Form 20-F). The company assumes no
liability whatsoever to update these forward-looking statements or to confirm
them to future events or developments.

    Contact:
    Kathrin Statz, +49-2173-384019
    Kathrin.statz@bayerhealthcare.com

Contact: Kathrin Statz, +49-2173-384019, Kathrin.statz at bayerhealthcare.com